Global Female Fertility Drug Pipeline Market Report 2022: Overview of 12 Drugs in Pipeline, Including Emerging Drugs – OXO-001 (Oxolife) and Nolasiban (ObsEva) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Female Infertility – Pipeline Insight, 2022” drug pipeline has been added to from ResearchAndMarkets.com offer.

This “Female Infertility – Pipeline Insight, 2022” report provides comprehensive insights on 12+ companies and 12+ drugs under development in the female infertility pipeline landscape.

It covers pipeline drug profiles, including clinical and non-clinical stage products. It also covers therapeutic evaluation by product type, stage, route of administration and molecule type. It further highlights inactive pipeline products in this space.

The report presents comprehensive information on the current scenario and growth prospects across the indication. A detailed picture of the Female Infertility pipeline landscape is provided, which includes an overview of the disease and Female Infertility treatment guidelines.

The assessment part of the report includes an in-depth female infertility business assessment and clinical evaluation of the pipeline products under development.

In the report, a detailed description of the drug is given including the mechanism of action of the drug, clinical studies, NDA approvals (if any) and product development activities including technology, collaborations on female infertility, licensing, mergers and acquisitions, financing, designations and other product-related details.

Chapters on Emerging Female Infertility Drugs

This segment of the Female Infertility report contains its detailed analysis of various drugs at different stages of clinical development including Phase II, I, Preclinical and Discovery. It also helps to understand details of clinical trials, expressive pharmacological action, agreements and collaborations, as well as the latest news and press releases.

Emerging drugs for female infertility

OXO-001: Oxovia

OXO-001, a first-class oral drug that acts directly on the endometrium to improve and enhance the embryo implantation process, which is a breakthrough innovation in reproductive medicine. After demonstrating its efficacy in preclinical trials and its safety in humans, Oxolife has already launched an international phase II clinical trial (OXOART2) with the drug.

The main objective of this ongoing clinical trial is to demonstrate the effectiveness of OXO-001 in increasing the pregnancy rate of infertile women. Another research with OXO-001 is an innovative approach to PCOS infertility treatment. Previous preclinical studies performed have shown that OXO-001 is able to recover ovulation and fertility in an animal model with features of PCOS, and we are currently in the late stages of preclinical development for this condition.

Nolasiban: ObsEva

ObsEva is currently advancing nolasiban (OBE001), an oral oxytocin receptor antagonist with the potential to decrease contractions, improve uterine blood flow, and improve endometrial receptivity to implantation of embryos. This increases the chances of a successful pregnancy and live birth in patients undergoing embryo transfer after ART.

The Phase 2 IMPLANT 1 clinical trial (n=247) showed that a single oral dose of 900 mg nolasiban approximately 4 h before fresh single or double embryo transfer, day 3, had the greatest increase in current pregnancy and lifetime birth rate compared to lower doses of 100 and 300 mg and placebo.

Female Infertility: Therapeutic Assessment

This segment of the report provides information about the different Female Infertility Drugs separated based on the following parameters which define the scope of the report such as:

Major players in female infertility

Approx. Over 12 key companies developing therapies for female infertility. Among the companies whose drug candidates against female infertility are at the most advanced stage, that is to say in phase II, are Oxolife.

Steps

This report covers about 12+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Intermediate products (Phase II)

  • Product at an early stage (Phase I)

  • Candidates in the preclinical and discovery phase

  • Abandoned and Inactive Candidates

  • Route of administration

Products have been categorized under various ROAs such as

  • Inhalation

  • Inhalation/Intravenous/Oral

  • intranasal

  • Intravenous

  • Intravenous/ Subcutaneous

  • N / A

  • Oral

  • Oral/intranasal/subcutaneous

  • Parenteral

  • Subcutaneous

  • Molecule type

The products have been categorized under different types of molecules such as

  • Antibody

  • Antisense oligonucleotides

  • Immunotherapy

  • Monoclonal antibody

  • peptides

  • Protein

  • Recombinant protein

  • small molecule

  • Stem cell

  • Vaccine

  • type of product

Female Infertility: Pipeline Development Activities

The report provides an overview of different therapeutic candidates in phase II, I, preclinical and discovery. It also analyzes the key female infertility therapeutic drug players involved in the development of key drugs.

Pipeline development activities

The report covers the detailed information on collaborations, acquisitions and mergers, licenses as well as in-depth therapeutic evaluation of emerging drugs for female infertility.

Overview of Female Infertility Report

  • Female Infertility Pipeline Analysis

  • Therapeutic assessment

  • Unmet needs

  • Impact of drugs

Evaluation of female infertility report

  • Pipeline Product Profiles

  • Therapeutic assessment

  • Pipeline assessment

  • Evaluation of inactive drugs

  • Unmet needs

Key players

  • Oxolife

  • ObsEva

  • Shandong TheraWisdom Biopharma Co., Ltd.

  • Jiangsu HengRui Medicine Co., Ltd.

  • Spruce Biosciences

  • EffRx

  • Ogeda

  • KinDex Pharmaceuticals

  • Forendo Pharma

Key products

  • OXO-001

  • Nolasiban

  • TWP-201

  • SHR7280

  • Tildacer font

  • EX-404

  • fezolinbeing

  • KDT-501

  • HSD17B5 inhibitor

For more information about this Drug Pipelines report, visit https://www.researchandmarkets.com/r/24h5lw

Comments are closed.